Tributary Capital Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-4,890
| Closed | -$392K | – | 148 |
|
|
2026
Q1 | $392K | Sell |
4,890
-130
| -3% | -$10.7K | 0.04% | 140 |
|
|
2025
Q4 | $428K | Sell |
5,020
-100
| -2% | -$8.21K | 0.04% | 134 |
|
|
2025
Q3 | $398K | Sell |
5,120
-305
| -6% | -$23.8K | 0.04% | 142 |
|
|
2025
Q2 | $424K | Buy |
5,425
+1,300
| +32% | +$97K | 0.04% | 136 |
|
|
2025
Q1 | $299K | Sell |
4,125
-1,900
| -32% | -$136K | 0.03% | 153 |
|
|
2024
Q4 | $446K | Sell |
6,025
-335
| -5% | -$23.4K | 0.03% | 130 |
|
|
2024
Q3 | $420K | Sell |
6,360
-200
| -3% | -$14.5K | 0.03% | 146 |
|
|
2024
Q2 | $606K | Sell |
6,560
-400
| -6% | -$35.4K | 0.05% | 112 |
|
|
2024
Q1 | $665K | Hold |
6,960
| – | – | 0.05% | 110 |
|
|
2023
Q4 | $531K | Sell |
6,960
-200
| -3% | -$13.9K | 0.04% | 128 |
|
|
2023
Q3 | $496K | Sell |
7,160
-100
| -1% | -$8.04K | 0.05% | 126 |
|
|
2023
Q2 | $685K | Buy |
7,260
+2,600
| +56% | +$226K | 0.06% | 96 |
|
|
2023
Q1 | $386K | Sell |
4,660
-100
| -2% | -$7.86K | 0.04% | 145 |
|
|
2022
Q4 | $355K | Sell |
4,760
-100
| -2% | -$7.71K | 0.04% | 146 |
|
|
2022
Q3 | $402K | Sell |
4,860
-40
| -0.8% | -$3.85K | 0.04% | 132 |
|
|
2022
Q2 | $466K | Sell |
4,900
-100
| -2% | -$10.4K | 0.05% | 120 |
|
|
2022
Q1 | $589K | Sell |
5,000
-200
| -4% | -$22.4K | 0.05% | 173 |
|
|
2021
Q4 | $674K | Sell |
5,200
-225
| -4% | -$26.2K | 0.05% | 167 |
|
|
2021
Q3 | $614K | Sell |
5,425
-1,600
| -23% | -$183K | 0.05% | 168 |
|
|
2021
Q2 | $728K | Hold |
7,025
| – | – | 0.06% | 163 |
|
|
2021
Q1 | $588K | Buy |
7,025
+1,225
| +21% | +$104K | 0.05% | 175 |
|
|
2020
Q4 | $529K | Sell |
5,800
-150
| -3% | -$12.4K | 0.04% | 180 |
|
|
2020
Q3 | $475K | Sell |
5,950
-150
| -2% | -$11.7K | 0.04% | 180 |
|
|
2020
Q2 | $422K | Sell |
6,100
-290
| -5% | -$20.6K | 0.04% | 184 |
|
|
2020
Q1 | $402K | Sell |
6,390
-240
| -4% | -$17.3K | 0.04% | 174 |
|
|
2019
Q4 | $516K | Sell |
6,630
-27,450
| -81% | -$2.14M | 0.04% | 182 |
|
|
2019
Q3 | $2.5M | Sell |
34,080
-25,320
| -43% | -$1.78M | 0.18% | 71 |
|
|
2019
Q2 | $3.66M | Sell |
59,400
-2,100
| -3% | -$127K | 0.26% | 64 |
|
|
2019
Q1 | $3.92M | Buy |
61,500
+18,300
| +42% | +$1.04M | 0.28% | 64 |
|
|
2018
Q4 | $2.21M | Sell |
43,200
-3,000
| -6% | -$152K | 0.2% | 72 |
|
|
2018
Q3 | $2.68M | Sell |
46,200
-1,200
| -3% | -$58.7K | 0.2% | 69 |
|
|
2018
Q2 | $2.3M | Sell |
47,400
-900
| -2% | -$42K | 0.18% | 79 |
|
|
2018
Q1 | $2.25M | Sell |
48,300
-900
| -2% | -$39.1K | 0.19% | 74 |
|
|
2017
Q4 | $1.85M | Sell |
49,200
-17,400
| -26% | -$639K | 0.16% | 96 |
|
|
2017
Q3 | $2.43M | Buy |
66,600
+14,400
| +28% | +$549K | 0.21% | 68 |
|
|
2017
Q2 | $2.06M | Sell |
52,200
-4,500
| -8% | -$164K | 0.18% | 86 |
|
|
2017
Q1 | $1.78M | Sell |
56,700
-8,100
| -13% | -$254K | 0.17% | 98 |
|
|
2016
Q4 | $2.02M | Sell |
64,800
-2,700
| -4% | -$87.5K | 0.24% | 96 |
|
|
2016
Q3 | $2.71M | Sell |
67,500
-14,700
| -18% | -$554K | 0.35% | 83 |
|
|
2016
Q2 | $2.73M | Sell |
82,200
-1,200
| -1% | -$41.1K | 0.4% | 83 |
|
|
2016
Q1 | $2.45M | Hold |
83,400
| – | – | 0.39% | 93 |
|
|
2015
Q4 | $2.2M | Sell |
83,400
-9,000
| -10% | -$234K | 0.36% | 97 |
|
|
2015
Q3 | $2.19M | Buy |
92,400
+68,400
| +285% | +$1.65M | 0.36% | 101 |
|
|
2015
Q2 | $570K | Buy |
+24,000
| New | +$542K | 0.09% | 173 |
|
Other funds holding EW
Tributary Capital Management's EW Position: Q2 2026 in Review
Tributary Capital Management sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 4,890 shares — an estimated $392K sold.
Tributary Capital Management first reported a position in EW in Q2 2015 and held it in 44 quarters. The position peaked at $3.92M in Q1 2019. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Tributary Capital Management reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
- Tributary Capital Management sold 4,890 Edwards Lifesciences shares in Q2 2026, an estimated $392K.
- Tributary Capital Management first reported a position in Edwards Lifesciences in Q2 2015 and held it in 44 quarters.
- Tributary Capital Management's Edwards Lifesciences position peaked at $3.92M in Q1 2019.
- 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Tributary Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.